Brean Capital Downgrades Keryx Biopharmaceuticals (KERX) to Hold
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Brean Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Hold.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
- Kepler Cheuvreux Downgrades Avantium N.V (AVTX:NA) to Reduce
Create E-mail Alert Related Categories
DowngradesRelated Entities
Brean CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
